State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.
Jiangsu Co-innovation Center for the Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, China.
J Virol. 2021 Aug 10;95(17):e0060321. doi: 10.1128/JVI.00603-21.
Since 2015, severe hydropericardium-hepatitis syndrome (HHS) associated with a novel fowl adenovirus 4 (FAdV-4) has emerged in China, representing a new challenge for the poultry industry. Although various highly pathogenic FAdV-4 strains have been isolated, the virulence factor and the pathogenesis of novel FAdV-4 are unclear. In our previous studies, we reported that a large genomic deletion (1,966 bp) is not related to increased virulence. Here, two recombinant chimeric viruses, rHN20 strain and rFB2 strain, were generated from a highly pathogenic FAdV-4 strain by replacing the or gene of a nonpathogenic FAdV-4, respectively. Both chimeric strains showed similar titers to the wild-type strain . Notably, rFB2 and the wild-type strain induced 100% mortality, while no mortality or clinical signs appeared in chickens inoculated with rHN20, indicating that hexon, but not fiber-2, determines the novel FAdV-4 virulence. Furthermore, an R188I mutation in the hexon protein identified residue 188 as the key amino acid for the reduced pathogenicity. The rR188I mutant strain was significantly neutralized by chicken serum and , whereas the wild-type strain was able to replicate efficiently. Finally, the immunogenicity of the rescued rR188I was investigated. Nonpathogenic rR188I provided full protection against lethal FAdV-4 challenge. Collectively, these findings provide an in-depth understanding of the molecular basis of novel FAdV-4 pathogenicity and present rR188I as a potential live attenuated vaccine candidate or a novel vaccine vector for HHS vaccines. HHS associated with a novel FAdV-4 infection in chickens has caused huge economic losses to the poultry industry in China since 2015. The molecular basis for the increased virulence remains largely unknown. Here, we demonstrate that the hexon gene is vital for FAdV-4 pathogenicity. Furthermore, we show that the amino acid residue at position 188 of the hexon protein is responsible for pathogenicity. Importantly, the rR188I mutant strain was neutralized by chicken serum and , whereas the wild-type strain was not. Further, the rR188I mutant strain provided complete protection against FAdV-4 challenge. Our results provide a molecular basis of the increased virulence of novel FAdV-4. We propose that the rR188I mutant is a potential live attenuated vaccine against HHS and a new vaccine vector for HHS-combined vaccines.
自 2015 年以来,一种新型的禽腺病毒 4(FAdV-4)引起的严重心包炎-肝炎综合征(HHS)在中国出现,这对家禽业构成了新的挑战。尽管已经分离出各种高致病性 FAdV-4 株,但新型 FAdV-4 的毒力因子和发病机制尚不清楚。在我们之前的研究中,我们报道了一个大的基因组缺失(1966bp)与毒力增加无关。在这里,我们通过用非致病性 FAdV-4 的替换了一个高致病性 FAdV-4 的或 基因,从一个高致病性 FAdV-4 株中生成了两个重组嵌合病毒,rHN20 株和 rFB2 株。这两种嵌合株的滴度与野生型株相似。值得注意的是,rFB2 和野生型株均能诱导 100%的死亡率,而 rHN20 株接种的鸡没有死亡或临床症状,表明衣壳蛋白,而不是纤维蛋白-2,决定了新型 FAdV-4 的毒力。此外,衣壳蛋白中 R188I 突变鉴定出 188 位残基是降低致病性的关键氨基酸。rR188I 突变株能被鸡血清和显著中和,而野生型株能有效地复制。最后,研究了拯救的 rR188I 的免疫原性。非致病性 rR188I 能完全保护鸡免受致死性 FAdV-4 的攻击。总之,这些发现深入了解了新型 FAdV-4 致病性的分子基础,并提出 rR188I 是 HHS 疫苗的一种潜在的活减毒疫苗候选物或新型疫苗载体。
自 2015 年以来,一种新型的禽腺病毒 4(FAdV-4)引起的严重心包炎-肝炎综合征(HHS)在中国出现,这对家禽业构成了新的挑战。尽管已经分离出各种高致病性 FAdV-4 株,但新型 FAdV-4 的毒力因子和发病机制尚不清楚。在我们之前的研究中,我们报道了一个大的基因组缺失(1966bp)与毒力增加无关。在这里,我们通过用非致病性 FAdV-4 的替换了一个高致病性 FAdV-4 的或 基因,从一个高致病性 FAdV-4 株中生成了两个重组嵌合病毒,rHN20 株和 rFB2 株。这两种嵌合株的滴度与野生型株相似。值得注意的是,rFB2 和野生型株均能诱导 100%的死亡率,而 rHN20 株接种的鸡没有死亡或临床症状,表明衣壳蛋白,而不是纤维蛋白-2,决定了新型 FAdV-4 的毒力。此外,衣壳蛋白中 R188I 突变鉴定出 188 位残基是降低致病性的关键氨基酸。rR188I 突变株能被鸡血清和显著中和,而野生型株能有效地复制。最后,研究了拯救的 rR188I 的免疫原性。非致病性 rR188I 能完全保护鸡免受致死性 FAdV-4 的攻击。总之,这些发现深入了解了新型 FAdV-4 致病性的分子基础,并提出 rR188I 是 HHS 疫苗的一种潜在的活减毒疫苗候选物或新型疫苗载体。
自 2015 年以来,一种新型的禽腺病毒 4(FAdV-4)引起的严重心包炎-肝炎综合征(HHS)在中国出现,这对家禽业构成了新的挑战。尽管已经分离出各种高致病性 FAdV-4 株,但新型 FAdV-4 的毒力因子和发病机制尚不清楚。在我们之前的研究中,我们报道了一个大的基因组缺失(1966bp)与毒力增加无关。在这里,我们通过用非致病性 FAdV-4 的替换了一个高致病性 FAdV-4 的或 基因,从一个高致病性 FAdV-4 株中生成了两个重组嵌合病毒,rHN20 株和 rFB2 株。这两种嵌合株的滴度与野生型株相似。值得注意的是,rFB2 和野生型株均能诱导 100%的死亡率,而 rHN20 株接种的鸡没有死亡或临床症状,表明衣壳蛋白,而不是纤维蛋白-2,决定了新型 FAdV-4 的毒力。此外,衣壳蛋白中 R188I 突变鉴定出 188 位残基是降低致病性的关键氨基酸。rR188I 突变株能被鸡血清和显著中和,而野生型株能有效地复制。最后,研究了拯救的 rR188I 的免疫原性。非致病性 rR188I 能完全保护鸡免受致死性 FAdV-4 的攻击。总之,这些发现深入了解了新型 FAdV-4 致病性的分子基础,并提出 rR188I 是 HHS 疫苗的一种潜在的活减毒疫苗候选物或新型疫苗载体。